Pharmacogenomic Score Can Personalize Treatment of Leukemia in Children

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Aug. 7, 2024 -- For pediatric patients with acute myeloid leukemia (AML), a pharmacogenomics-based 10 single nucleotide polymorphism cytarabine (Ara-C) score (ACS10) can be used to tailor induction regimens, yielding improved outcomes, according to a study published online July 30 in Clinical Cancer Research.

Noting that low ACS10 has been shown to be associated with poor outcome in AML patients treated with standard chemotherapy, Richard J. Marrero, Pharm.D., from the University of Florida College of Pharmacy in Gainesville, and colleagues examined the ACS10 score in the context of three induction regimens. Low versus high ACS10 score groups were assessed for event-free (EFS) and overall survival (OS) among patients in two clinical trials (AML02 and AML08): AML02 low-dose cytarabine (LDAC; 91 patients), AML02+AML08 high-dose cytarabine (HDAC; 194 patients), and AML08 clofarabine+cytarabine (Clo/Ara-C; 105 patients).

The researchers found that patients treated with Clo/Ara-C had significantly improved EFS and OS compared with LDAC within the low ACS10 score group (score ≤0; hazard ratios, 0.45 and 0.44, respectively). Within the high ACS10 score group (score >0), augmentation with Clo/Ara-C was not favorable compared with LDAC for EFS or OS (hazard ratios, 1.95 and 2.17). Compared with nonpersonalized approaches, personalized models predicted 9 percent improvement in outcome in ACS10 score-based tailored induction (Clo/Ara-C for low- and LDAC for high-ACS10 score groups).

"Given the genetic basis of the score, it could be used by clinicians preemptively to match patients with the most effective treatment regimen to lead to remission," lead author Jatinda Lamba, Ph.D., also from the University of Florida, said in a statement.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-08 01:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords